Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insmed Incorporated - Common Stock (NQ:INSM)

160.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 160.18
Bid (Size) 156.00 (100)
Ask (Size) 170.00 (100)
Prev. Close 160.18
Today's Range 160.18 - 160.18
52wk Range 60.40 - 212.75
Shares Outstanding 115,246,666
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-9.6%
-9.6%
1 Month
+11.9%
+11.9%
3 Month
-9.0%
-9.0%
6 Month
-1.0%
-1.0%
1 Year
+146.5%
+146.5%

More News

Read More
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
Via The Motley Fool
News headline image
The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Insmed (INSM) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗
Via The Motley Fool
Topics Stocks
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit ↗
Via Stocktwits
News headline image
Wondering what's happening in today's after-hours session? ↗
Via Chartmill

Frequently Asked Questions

Is Insmed Incorporated - Common Stock publicly traded?
Yes, Insmed Incorporated - Common Stock is publicly traded.
What exchange does Insmed Incorporated - Common Stock trade on?
Insmed Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Insmed Incorporated - Common Stock?
The ticker symbol for Insmed Incorporated - Common Stock is INSM on the Nasdaq Stock Market
What is the current price of Insmed Incorporated - Common Stock?
The current price of Insmed Incorporated - Common Stock is 160.18
When was Insmed Incorporated - Common Stock last traded?
The last trade of Insmed Incorporated - Common Stock was at 04/08/26 04:00 PM ET
What is the market capitalization of Insmed Incorporated - Common Stock?
The market capitalization of Insmed Incorporated - Common Stock is 18.46B
How many shares of Insmed Incorporated - Common Stock are outstanding?
Insmed Incorporated - Common Stock has 18B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.